Navigation Links
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
Date:5/4/2008

MISSISSAUGA, ON, May 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on its pain management product AeroLEF(TM) will be presented at The 27th Annual Scientific Meeting of the American Pain Society, which takes place May 8-10, 2008 in Tampa, Florida.

The first poster presentation, entitled "A randomized controlled trial demonstrates the efficacy, safety and tolerability of Aerosolized free and Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration", is scheduled to be presented on Thursday, May 8, 2008 (Abstract #8448, Poster Board number 265).

The second poster presentation, entitled "Comparative phase I PK study of Aerosolized free and Liposome-Encapsulated Fentanyl (AeroLEF(TM)) demonstrates rapid and extended plasma fentanyl concentrations following inhalation", is scheduled to be presented on Thursday, May 8, 2008 (Abstract # 8395, Poster Board number 243).

The third poster presentation, entitled "Aerosolized Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration allows patients with moderate to severe post-surgical acute pain to self-titrate to effective analgesia", is scheduled to be presented on Friday, May 9, 2008 (Abstract # 8435, Poster Board number 264).

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
2. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
3. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
7. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
8. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging bio and technology start-ups, is hosting “Celebration ... 2017. This double event will start with libations and networking at 3:30 p.m. ...
(Date:4/20/2017)... ... April 20, 2017 , ... Assured Enterprises, Inc. ... a full spectrum of digital security goods and services. The strategic partners now ... ground-breaking proactive cybersecurity services and products through Assured Enterprises. The two companies provide ...
(Date:4/20/2017)... Maine (PRWEB) , ... April 20, 2017 , ... ... contributions to the scientific and clinical research community’s growing body of knowledge during ... 2017 in the Gracie Theatre and the adjacent Darling Atrium. During the event, ...
(Date:4/20/2017)... MA (PRWEB) , ... April 20, 2017 , ... ... brightness light sources for advanced technology applications, announced today that Chief Executive Officer ... (NAAB). , SEMI is the global industry association connecting the electronics ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):